Standard Chemical & Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Standard Chemical & Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	36.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

Apr 13

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 19

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Jan 04

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

Dec 22

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Dec 08

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Standard Chemical & Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1720 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	6,240	835	708	1,337	N/A
9/30/2023	6,231	848	501	1,175	N/A
6/30/2023	6,135	863	636	1,307	N/A
3/31/2023	6,107	853	11	1,277	N/A
12/31/2022	5,851	815	28	1,228	N/A
9/30/2022	5,501	813	168	1,232	N/A
6/30/2022	5,072	734	37	1,004	N/A
3/31/2022	4,740	672	549	861	N/A
12/31/2021	4,604	707	609	827	N/A
9/30/2021	4,489	694	740	961	N/A
6/30/2021	4,413	649	598	888	N/A
3/31/2021	4,372	612	686	979	N/A
12/31/2020	4,305	524	570	923	N/A
9/30/2020	4,219	461	427	774	N/A
6/30/2020	4,223	455	411	667	N/A
3/31/2020	4,125	425	369	603	N/A
12/31/2019	3,937	376	473	652	N/A
9/30/2019	3,905	374	475	648	N/A
6/30/2019	3,769	383	514	678	N/A
3/31/2019	3,656	383	296	444	N/A
12/31/2018	3,573	374	315	485	N/A
9/30/2018	3,480	329	225	398	N/A
6/30/2018	3,624	366	315	525	N/A
3/31/2018	3,702	367	590	806	N/A
12/31/2017	3,849	363	322	709	N/A
9/30/2017	3,898	393	N/A	546	N/A
6/30/2017	3,761	347	N/A	327	N/A
3/31/2017	3,725	319	N/A	241	N/A
12/31/2016	3,674	340	N/A	305	N/A
9/30/2016	3,635	338	N/A	615	N/A
6/30/2016	3,529	323	N/A	699	N/A
3/31/2016	3,374	325	N/A	683	N/A
12/31/2015	3,321	348	N/A	644	N/A
9/30/2015	3,280	345	N/A	558	N/A
6/30/2015	3,275	349	N/A	525	N/A
3/31/2015	3,304	381	N/A	535	N/A
12/31/2014	3,296	374	N/A	581	N/A
9/30/2014	3,203	334	N/A	478	N/A
6/30/2014	3,125	292	N/A	485	N/A
3/31/2014	3,069	277	N/A	561	N/A
12/31/2013	3,054	299	N/A	435	N/A
9/30/2013	3,207	331	N/A	406	N/A
6/30/2013	3,277	350	N/A	412	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1720's forecast earnings growth is above the savings rate (0.8%).

Earnings vs Market: Insufficient data to determine if 1720's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1720's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1720's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1720's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1720's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Standard Chemical & Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022)

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$1.33 (vs NT$1.28 in 2Q 2022)

Upcoming dividend of NT$2.50 per share at 3.8% yield

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Investor sentiment improves as stock rises 22%

Full year 2022 earnings released: EPS: NT$4.56 (vs NT$3.96 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$1.34 (vs NT$0.89 in 3Q 2021)

Now 20% undervalued

Now 20% undervalued

Second quarter 2022 earnings released: EPS: NT$1.28 (vs NT$0.93 in 2Q 2021)

Upcoming dividend of NT$2.50 per share

First quarter 2022 earnings released: EPS: NT$0.97 (vs NT$1.17 in 1Q 2021)

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.89 (vs NT$0.64 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.73 in 2Q 2020)

Upcoming dividend of NT$1.80 per share

First quarter 2021 earnings released: EPS NT$1.17 (vs NT$0.67 in 1Q 2020)

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.

Full year 2020 earnings released: EPS NT$2.93 (vs NT$2.11 in FY 2019)

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

New 90-day low: NT$35.20

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: NT$36.50

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS NT$0.64

New 90-day low: NT$37.55

New 90-day low: NT$37.70

New 90-day low - NT$38.30

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies